Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Novel diabetes gene discovery through comprehensive characterization and integrative analysis of longitudinal gene expression changes

ABSTRACT: Novel diabetes gene discovery through comprehensive characterization and integrative analysis of longitudinal gene expression changes

PROVIDER: PRJNA762935 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15881900_1.fastq.gz	Fastqsanger.gz
	SRR15881900_2.fastq.gz	Fastqsanger.gz
	SRR15881901_1.fastq.gz	Fastqsanger.gz
	SRR15881901_2.fastq.gz	Fastqsanger.gz
	SRR15881902_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 232

Similar Datasets

Novel diabetes gene discovery through comprehensive characterization and integrative analysis of longitudinal gene expression changes

Project description:Type 2 diabetes is a complex, systemic disease affected by both genetic and environmental factors. Previous research has identified genetic variants associated with type 2 diabetes risk, however gene regulatory changes underlying progression to disease are still largely unknown. We investigated RNA expression changes that occur during diabetes progression using a two-stage approach. In our discovery stage, we compared changes in gene expression using two longitudinally collected blood samples from subjects who transitioned to type 2 diabetes between the time points against those who did not with a novel analytical network approach. Our network methodology identified 17 networks, one of which was significantly associated with transition status. This 822-gene network harbors many genes novel to the type 2 diabetes literature, but is also significantly enriched for genes previously associated with type 2 diabetes in GWAS. In the validation stage, we queried associations of genetically determined expression with diabetes-related traits in a large biobank with linked electronic health records. We observed a significant enrichment of genes in our identified network whose genetically determined expression is associated with type 2 diabetes and other metabolic traits and validated 31 gene-level associations that have never been reported by previous type 2 diabetes GWAS. Finally, we performed functional validation, demonstrating that the genes in this network are enriched in enhancers that operate in human pancreatic islet cells. We present an innovative and systematic approach that identified and validated key gene expression changes associated with type 2 diabetes transition status and demonstrated their translational relevance in a large clinical resource.

2021-09-16 | GSE184050 | GEO

Novel diabetes gene discovery through comprehensive characterization and integrative analysis of longitudinal gene expression changes.

Project description:Type 2 diabetes is a complex, systemic disease affected by both genetic and environmental factors. Previous research has identified genetic variants associated with type 2 diabetes risk; however, gene regulatory changes underlying progression to metabolic dysfunction are still largely unknown. We investigated RNA expression changes that occur during diabetes progression using a two-stage approach. In our discovery stage, we compared changes in gene expression using two longitudinally collected blood samples from subjects whose fasting blood glucose transitioned to a level consistent with type 2 diabetes diagnosis between the time points against those who did not with a novel analytical network approach. Our network methodology identified 17 networks, one of which was significantly associated with transition status. This 822-gene network harbors many genes novel to the type 2 diabetes literature but is also significantly enriched for genes previously associated with type 2 diabetes. In the validation stage, we queried associations of genetically determined expression with diabetes-related traits in a large biobank with linked electronic health records. We observed a significant enrichment of genes in our identified network whose genetically determined expression is associated with type 2 diabetes and other metabolic traits and validated 31 genes that are not near previously reported type 2 diabetes loci. Finally, we provide additional functional support, which suggests that the genes in this network are regulated by enhancers that operate in human pancreatic islet cells. We present an innovative and systematic approach that identified and validated key gene expression changes associated with type 2 diabetes transition status and demonstrated their translational relevance in a large clinical resource.

| S-EPMC9476627 | biostudies-literature

Longitudinal DNA methylation differences precede type 1 diabetes

Project description:DNA methylation may be involved in development of type 1 diabetes (T1D), but previous epigenome-wide association studies were conducted among cases with clinically diagnosed diabetes. Using multiple pre-disease peripheral blood samples on the Illumina 450K and EPIC platforms, we investigated longitudinal methylation differences between 87 T1D cases and 87 controls from the prospective Diabetes Autoimmunity Study in the Young (DAISY) cohort. Change in methylation with age differed between cases and controls in 10 regions. Average longitudinal methylation differed between cases and controls at two genomic positions and 28 regions. Some methylation differences were detectable and consistent as early as birth, including before and after the onset of preclinical islet autoimmunity. Results map to transcription factors, other protein coding genes, and non-coding regions of the genome with regulatory potential. The identification of methylation differences that predate islet autoimmunity and clinical diagnosis may suggest a role for epigenetics in T1D pathogenesis.

2020-03-09 | GSE142512 | GEO

Longitudinal DNA methylation differences precede type 1 diabetes

Project description:Longitudinal DNA methylation differences precede type 1 diabetes

| PRJNA597238 | ENA

Integrative discovery of treatments for high-risk neuroblastoma

Project description:Integrative discovery of treatments for high-risk neuroblastoma

| PRJNA495016 | ENA

Discovery of a Drug Candidate for GLIS3-Associated Diabetes

Project description:Discovery of a Drug Candidate for GLIS3-Associated Diabetes

| PRJNA463329 | ENA

Urinary sediment transcriptomic and longitudinal data to investigate renal function decline in type 1 diabetes

Project description:Using a discovery/validation approach we investigated associations between a panel of genes selected from a transcriptomic study and the renal function decline across time in a cohort of type 1 diabetes patients.

2019-11-19 | GSE140627 | GEO

Gene expression profile of syphilis complicated with diabetes

Project description:To further investigate the pathogenesis of syphilis with diabetes, we used a gene chip expression profile from a rabbit model of syphilis with diabetes as a discovery platform to identify potential genes. Grouped into normal control group (n=2) and syphilis combined with diabetes group (n=3).

2020-05-06 | GSE135053 | GEO

An integrative analysis of skeletal muscle insulin resistance

Project description:We aim to identify a novel pathway to regulate insulin resistance from transcriptional profiles of skeletal muscles from patients with diabetes and to demonstrate its role in experimental models of insulin resistance. We performed transcriptional profiling of skeletal muscles from subjects with or without diabetes. Through an integrative analysis of our dataset with four previous datasets, we identified the core gene sets associated with insulin resistance.

2015-09-01 | E-MTAB-3420 | biostudies-arrayexpress

Serum APOC1 levels are decreased in seroconverted children who progress to type 1 diabetes at a young age

Project description:Biomarkers are needed to accurately predict and monitor type 1 diabetes progression during the substantially heterogeneous presymptomatic period of the disease development. To address this concern, we studied temporal changes in the plasma and serum proteomes of < 5-year-old children with HLA-conferred risk for type 1 diabetes by analysing longitudinal sample series that were collected at regular intervals between birth and diagnosis. Using mass spectrometry-based discovery proteomics, longitudinal plasma sample series from multiple autoantibody positive children who had rapidly progressed to type 1 diabetes before 4 years of age were analysed and compared with similar measurements from age and gender matched children who were either single autoantibody positive or autoantibody negative. Following analysis of the data with an additive Gaussian process regression model (LonGP), targeted proteomics was used to verify 11 biomarker candidates in a larger independent yet similar cohort of children with more frequent sampling points. The data reiterated extensive age related trends for protein levels in young children. Further, by combining the utility of LonGP together with the targeted analysis in an extended cohort, these analyses demonstrated that the serum levels of two peptides unique for apolipoprotein C1 (APOC1) were decreased after the appearance of the first autoantibody and remained relatively less abundant in children who progressed to type 1 diabetes in comparison to autoantibody negative children.

2023-09-26 | PXD033744 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data